Advertisement

Clinical Oral Investigations

, Volume 17, Issue 5, pp 1365–1373 | Cite as

Inflammatory cells of immunosuppressive phenotypes in oral lichen planus have a proinflammatory pattern of expression and are associated with clinical parameters

  • Marilena VeredEmail author
  • Eran Fürth
  • Yifat Shalev
  • Dan Dayan
Original Article

Abstract

Objectives

We sought to investigate the expression of cells with immunosuppressive/protumorigenic phenotypes in oral lichen planus (OLP), such as M2-tumor-associated macrophages (TAM2), myeloid-derived suppressive cells (MDSCs), and regulatory T cells (Tregs) in association with clinical parameters.

Materials and methods

Cases of hyperkeratotic (HK)-OLP (n = 23) and erosive (E)-OLP (n = 26) were immunohistochemically stained to determine the percentages of CD163-TAM2, CD80-MDSCs, and FOXP3-Tregs of proinflammatory CD121a-Th17, CD4 and CD8 lymphocytes, and of cells positive for nuclear factor kappa B (NF-κB) and transforming growth factor beta. Clinical parameters included symptoms, treatment approach, treatment response, and others.

Results

The inflammatory infiltrate in HK-OLP and E-OLP contained immunosuppressive cells; however, their pattern of expression was compatible with a proinflammatory response [membranous CD163-TAM2 staining (not extracellular), CD80+ lymphocytes (not macrophages), and a few Tregs]. The presence of CD4+, CD8+, and CD121a+ T lymphocytes was extensive. TAM2 were more frequent in E-OLP than in HK-OLP (P = 0.017). A higher frequency of CD80+ lymphocytes was associated with partial to no response to treatment (P = 0.028). Nuclear expression of NF-κB in the inflammatory cells was absent.

Conclusions

The pattern of expression of the immunosuppressive cells, together with numerous CD4+, CD8+, and Th17-CD121a+ lymphocytes, suggest an extensive proinflammatory response rather than an immunosuppressive/protumorigenic response.

Clinical relevance

The frequency of selective types of inflammatory cells calls for individual profile analyses of inflammatory infiltrates and individually adjusted treatment.

Keywords

Oral lichen planus Tumor-associated macrophages Myeloid-derived suppressive cells Regulatory T cells Immune-suppressive/protumorigenic cells Novel treatment approach 

Notes

Acknowledgments

The authors would like to thank Mrs. Hana Vered for her technical assistance. Ms. Esther Eshkol is thanked for here editorial assistance. The study was supported by the Dave and Sarah Babish fund, School of Dental Medicine, Tel Aviv University.

Conflict of interest

None.

References

  1. 1.
    Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A (2010) Pathogenesis of oral lichen planus—a review. J Oral Pathol Med 39:729–734PubMedCrossRefGoogle Scholar
  2. 2.
    Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K (2005) Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:40–51PubMedCrossRefGoogle Scholar
  3. 3.
    Zhang J, Zhou G, Du GF, Xu XY, Zhou HM (2011) Biologics, an alternative therapeutic approach for oral lichen planus. J Oral Pathol Med 40:521–524PubMedCrossRefGoogle Scholar
  4. 4.
    Crincoli V, Di Bisceglie MB, Scivetti M, Lucchese A, Tecco S, Festa F (2011) Oral lichen planus: update on etiopathogenesis, diagnosis and treatment. Immunopharmacol Immunotoxicol 33:11–20PubMedCrossRefGoogle Scholar
  5. 5.
    El Naggar AK, Reichart PA (2005) Proliferative verrucous leukoplakia and precancerous condition. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds) World Organization Classification of tumours. Pathology and genetics. Head and neck tumours. IARC, Lyon, pp 180–181Google Scholar
  6. 6.
    Tao XA, Xia J, Chen XB, Wang H, Dai YH, Rhodus NL et al (2010) FOXP3 T regulatory cells in lesions of oral lichen planus correlated with disease activity. Oral Dis 16:76–82PubMedCrossRefGoogle Scholar
  7. 7.
    Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117:1155–1166PubMedCrossRefGoogle Scholar
  8. 8.
    Wang HY, Wang RF (2007) Regulatory T cells and cancer. Curr Opin Immunol 19:217–223PubMedCrossRefGoogle Scholar
  9. 9.
    Lee YK, Mukasa R, Hatton RD, Weaver CT (2009) Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 21:274–280PubMedCrossRefGoogle Scholar
  10. 10.
    Sato M, Tokuda N, Fukumoto T, Mano T, Sato T, Ueyama Y (2006) Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol Med 35:33–36PubMedCrossRefGoogle Scholar
  11. 11.
    Karin M, Greten FR (2005) NF-kappa B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749–759PubMedCrossRefGoogle Scholar
  12. 12.
    Phipps KD, Surette AP, O’Connell PA, Waisman DM (2011) Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res 71:6676–6683PubMedCrossRefGoogle Scholar
  13. 13.
    Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T (2009) Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB. J Pathol 219:143–152PubMedCrossRefGoogle Scholar
  14. 14.
    Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454:436–444PubMedCrossRefGoogle Scholar
  15. 15.
    Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175–1183PubMedCrossRefGoogle Scholar
  16. 16.
    Allavena P, Germano G, Marchesi F, Mantovani A (2011) Chemokines in cancer related inflammation. Exp Cell Res 317:664–673PubMedCrossRefGoogle Scholar
  17. 17.
    Sethi G, Sung B, Aggarwal BB (2008) Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 233:21–31CrossRefGoogle Scholar
  18. 18.
    Gannot G, Gannot I, Vered H, Buchner A, Keisari Y (2006) Increase in immune cell infiltration with progression of oral epithelium from hyperkeratosis to dysplasia and carcinoma. Br J Cancer 86:1444–1448CrossRefGoogle Scholar
  19. 19.
    Hirshberg A, Amariglio N, Akrish S, Yahalom R, Rosenbaum H, Okon E et al (2006) Traumatic ulcerative granuloma with stromal eosinophilia—a reactive lesion of the oral mucosa. Am J Clin Pathol 126:522–529PubMedCrossRefGoogle Scholar
  20. 20.
    Rogers HW, Sheehan KC, Brunt LM, Dower SK, Unanue ER, Schreiber RD (1992) Interleukin 1 participates in the development of anti-Listeria responses in normal and SCID mice. Proc Natl Acad Sci USA 89:1011–1015PubMedCrossRefGoogle Scholar
  21. 21.
    Massimo H, Ohguro N, Nomura S, Hashida N, Nakai K, Tano Y (2008) Neutrophil chemotaxis and local expression of interleukin-10 in the tolerance of endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 49:5450–5457CrossRefGoogle Scholar
  22. 22.
    Matsumoto Y, Horiike S, Ohshiro M, Yamamoto M, Sasaki N, Tsutsumi T et al (2010) Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol 133:281–290PubMedCrossRefGoogle Scholar
  23. 23.
    Lamb RJ, Capocasale RJ, Duffy KE, Sarisky RT, Mbow ML (2007) Identification and characterization of novel bone marrow myeloid DEC205+ Gr-1+ cell subsets that differentially express chemokine and TLRs. J Immunol 178:7833–7839PubMedGoogle Scholar
  24. 24.
    Quaranta MG, Mattioli B, Spadaro F, Straface E, Giordani L, Ramoni C et al (2003) HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells. FASEB 17:2025–2036CrossRefGoogle Scholar
  25. 25.
    Theilig F, Enke AK, Scolari B, Polzin D, Bachmann S, Koesters R (2011) TGF-β tubular deficiency of von Hippel-Lindau attenuates renal disease progression in anti-GBM glomerulonephritis. Am J Pathol 179:2177–2188PubMedCrossRefGoogle Scholar
  26. 26.
    Kastelan M, Prpić Massari L, Gruber F, Zamolo G, Zauhar G, Coklo M et al (2004) The role of perforin-mediated apoptosis in lichen planus lesions. Arch Dermatol Res 296:226–230PubMedCrossRefGoogle Scholar
  27. 27.
    Mignogna MD, Fedele S, Lo Russo L, Lo Muzio L, Bucci E (2004) Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence? Oral Oncol 40:120–130PubMedCrossRefGoogle Scholar
  28. 28.
    Timmermann M, Buck F, Sorg C, Hogger P (2004) Interaction of soluble CD163 with activated T lymphocytes involves its association with non-muscle myosin heavy chain type A. Immunol Cell Biol 82:479–487PubMedCrossRefGoogle Scholar
  29. 29.
    Ben-Neriah Y, Karin M (2011) Inflammation meets cancer, with NF-κB as the matchmaker. Nat Immunol 12:715–723PubMedCrossRefGoogle Scholar
  30. 30.
    Fuentes-Duculan J, Suárez-Fariñas M, Zaba LC, Nograles KE, Pierson KC, Mitsui H et al (2010) A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 130:2412–2422PubMedCrossRefGoogle Scholar
  31. 31.
    Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K (2005) Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 175:1586–1592PubMedGoogle Scholar
  32. 32.
    Long M, Park SG, Strickland I, Hayden MS, Ghosh S (2009) Nuclear factor-κB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity 31:921–931PubMedCrossRefGoogle Scholar
  33. 33.
    Torihata H, Ishikawa F, Okada Y, Tanaka Y, Uchida T, Suguro T et al (2004) Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells. Immunology 112:219–227PubMedCrossRefGoogle Scholar
  34. 34.
    Yang R, Cai Z, Zhang Y, Yutzy WH, Roby KF, Roden RB (2006) CD80 in immune suppression by mouse ovarian carcinoma–associated Gr-1+CD11b+ myeloid cells. Cancer Res 66:6807–6815PubMedCrossRefGoogle Scholar
  35. 35.
    Valmori D, Raffin C, Raimbaud I, Ayyoub M (2010) Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors. Proc Natl Acad Sci USA 107:19402–19407PubMedCrossRefGoogle Scholar
  36. 36.
    Liu G, Ma H, Qiu L, Li L, Cao Y, Ma J et al (2011) Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. Immunol Cell Biol 89:130–142PubMedCrossRefGoogle Scholar
  37. 37.
    Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K (2005) Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:164–178PubMedCrossRefGoogle Scholar
  38. 38.
    Keenan AV, Ferraiolo D (2011) Insufficient evidence for effectiveness of any treatment for oral lichen planus. Evid Based Dent 12:85–86PubMedCrossRefGoogle Scholar
  39. 39.
    Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A et al (2002) The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 13:350–365PubMedCrossRefGoogle Scholar
  40. 40.
    Mani H, Sidhu GS, Kumari R, Gaddipatil JP, Seth P, Maheshwari RK (2002) Curcumin differentially regulates TGF-β1, its receptors and nitric oxide synthase during impaired wound healing. Biofactors 16:29–43PubMedCrossRefGoogle Scholar
  41. 41.
    Fu S, Kurzrock R (2010) Development of curcumin as an epigenetic agent. Cancer 116:4670–4676PubMedCrossRefGoogle Scholar
  42. 42.
    Chainani-Wu N, Madden E, Lozada-Nur F, Silverman S (2011) High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol. doi: 10.1016/j.jaad.2011.04.022

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Marilena Vered
    • 1
    • 2
    Email author
  • Eran Fürth
    • 3
  • Yifat Shalev
    • 1
  • Dan Dayan
    • 1
  1. 1.Department of Oral Pathology and Oral Medicine, School of Dental MedicineTel Aviv UniversityTel AvivIsrael
  2. 2.Institute of PathologyThe Chaim Sheba Medical CenterTel HashomerIsrael
  3. 3.Oral and Maxillofacial Surgery UnitTel Aviv Sourasky Medical CenterTel AvivIsrael

Personalised recommendations